16 September 2026 editorial review · Trial
VCTX211: CRISPR gene-edited hypoimmune stem-cell islets: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT05565248; TERMINATED; updated 2026-05-07; enrollment 5 (ACTUAL); results not posted.
Endpoint comparison: Incidence of adverse events with causality related to VCTX211 units, the surgical procedures and/or medical interventions required to implant and explant the VCTX211 units. (From implantation up to 12 months post implantation); Assess the clinical efficacy of VCTX211 units via evaluation of C-peptide increase from the baseline. (From implantation up to 12 months post implantation).
Sources for this record: NCT05565248: study record (registry); CRISPR Therapeutics: January 2026 priorities and CTX211 update (manufacturer).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.
Selected cell-therapy and adjunct trial review — 16 September 2026
Outcome and correction: Corrected five enrolled versus assumed five dosed; reconciled no posted results with company-reported 12-month C-peptide; removed first-ever and validated-success claims.
Primary sources checked: Registry NCT05565248; CRISPR January 12, 2026 SEC-filed update.
Limits: Unquantified sponsor C-peptide statement, no patient-level or controlled outcome dataset.
Additional 16 September correction: inspected 3 August 2026 corporate update, slide 41. It adds company claims of no serious adverse events or adverse events of special interest, 12-month C-peptide and histologic insulin-cell survival despite device fibrosis and immune-cell infiltration. Summary, results and narrative now include this sponsor-only context; it supersedes the earlier description of a single brief C-peptide statement. The formal registry status remains terminated despite the slide describing Phase 1 as completed. Five enrolled is not assumed to mean five dosed or five contributing to each observation. Linked to the existing CTX213 programme item as predecessor context, with no successor human-efficacy inference. Full clinical results and participant-level safety interpretation remain limited.